Abstract
Heterozygous familial hypercholesterolemia (HFH) is increasingly better diagnosed and treatments can improve the cardiovascular prognosis. We evaluated the long-term cardiovascular risk of HFH using the French REFERCHOL registry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have